39 results about "Hla genotyping" patented technology

The invention is a method of determining HLA genotype for HLA-A, HLA-B, HLA-C, DQB1, DRB1, DRB3, DRB4, DRB5, DPA1 and DPB1. Reagents and kits are also disclosed.

The present invention discloses the use of Allele-Specific-Oligonucleotide (ASO) as a detection assay for human HLA classification. Using Reversed-Dot-Blotting format and flow through hybridization process, more efficient, faster and less expensive HLA classification can be achieved. A simplified procedure for HLA genotyping is also described. This invention further provides a Single Nucleotide Polymorphism (SNP)-based DNA fingerprining method for rapid and accurate genotyping, identification as well as DNA analyses of genetic data from human beings and different organisms. In addition this invention also discloses a new device for rapid and sensitive analyses of nucleic acids, proteins and other analysts for diagnosis.

The invention belongs to the technical field of gene engineering, and discloses a primer combination for HLA (human leukocyte antigen) genotyping, a kit containing the primer combination and a method for HLA genotyping. Thus, the sequence-specific HLA genotyping (GSA-SBT) technique is quick, simple, accurate and visual. The primer combination can be synchronously used for amplification and sequencing with the commercialized kit, thereby lowering the experimentation cost. Besides, the specific design of mismatched bases are introduced to the 3' terminal of the primer, thereby enhancing the specificity of the primer amplification and ensuring the accuracy of the typing result.

The present invention provides a portable system for real-time population-scale HLA genotyping and / or allelotyping in a field environment and methods of such population-scale HLA genotyping. The individual components of the system are portable to and operable within a field environment thereby providing high throughput with real-time geno- or allelotyping. Also provided are HLA gene-specific primers and HLA allele-specific or single nucleotide polymorphism-specific hybridization probes. In addition the present invention provides a microarray comprising the hybridization probes. Further provided is a kit comprising the HLA gene-specific primers and the microarray.

The invention provides a kit and method for typing an HLA gene. The kit comprises a primer for amplifying a second exon and a third exon of an HLA-B gene and a primer for amplifying a fourth exon of the HLA-B gene, wherein the primer for amplifying the second exon and the third exon of the HLA-B gene comprises an amplification primer pair composed of primer sequences as shown in SEQ ID NO.1 and SEQ ID NO.2; and the primer for amplifying the fourth exon of the HLA-B gene comprises an amplification primer pair composed of primer sequences as shown in SEQ ID NO.3 and SEQ ID NO.4. By using the kit and method provided by the invention, the typing process can be simpler, the typing resolution ratio and accuracy rate are increased while the cost is reduced, and furthermore the kit and method are further applied to scientific research and clinic work.

The present disclosure relates to a composition and method for management of Osteoarthritis, including improvement in pain and cartilage regeneration of knee joint affected by osteoarthritis. The present disclosure also relates to a kit for treating Osteoarthritis and the method of assembling the same. The present disclosure relates to a pooled allogeneic mesenchymal stromal cell composition from multiple donors with diverse HLA genotypes suitable for transplantation into a diverse population without the risk of rejection. The pooled cell composition of the present disclosure shows increased potency and higher chondrogenic differentiation potential.

The invention discloses a parting method of leucocyte antigen gene of human being, comprising the following steps of: (1) extracting genome DNA to be tested by a regular technology, and amplifying a destination gene fragment to be analyzed by using PCR amplification primer: 2,3,4 exon of HLA-A, 2,3,4 exon of HLA-B and exon on the locus 2 of HLA-DRB; and (2) amplifying the PCR output obtained in the step (1) by using sequencing primer, amplifying the exon, sequencing the amplified exon and comparing the sequencing result with the standard sequence in a database to determine the gene parting result. As the 2,3,4 exon of HLA-A, 2,3,4 exon of HLA-B and exon on the locus 2 of HLA-DRB are effectively amplified as a result of optimized combination of the HLA gene sequencing kit and the test condition, and the corresponding exon is sequenced, the invention solves the problem that effective parting can not be performed when certain allelic gene nucleotide is located outside an amplification area during further parting, thereby improving the parting resolution and accuracy of the HLA gene.

The invention provides a PCR sequencing method, wherein the combination of primer indexes, DNA incomplete shearing strategy and the second generation sequencing technique (Paired-End sequencing technique) can make the length of PCR products that can be sequenced by a sequencer longer than the maximum sequencing length of the sequencer while making full use of the characteristics of the second generation sequencing technique such as high throughput and low cost, thereby greatly broadening its applicable scope. In addition, the present invention also provides primer indexes for the PCR sequencing method and the use of the method in genotyping, particularly in HLA analysis, and also provides the PCR primers used, particularly the PCR primers for HLA-A, B, HLA-C and HLA-DQB1 gene.

Disclosed and claimed are compositions and methods for therapy and / or prevention of restenosis and / or atherosclerosis. The compositions can include an agent for decreasing viral load of cytomegalovirus, such as an immunological composition or vaccine against cytomegalovirus (CMV) containing at least one epitope of interest of CMV and / or an expression system which expresses at least one epitope of interest of CMV. Such compositions can include at least one epitope of p53. Alternatively, the compositions can include at least one epitope of p53 and / or an expression system which expresses the epitope. The methods can include administering the compositions to a patient in need of such therapy and / or prevention. Additionally, compositions and methods for diagnosing atherosclerosis and / or restenosis, or susceptibility thereto, including screening a sample from a patient for antibodies to CMV and / or CMV proteins and / or screening a sample from a patient for specific viral proteins that predict whether the virus has been reactivated and / or antibodies thereto and / or detecting whether CMV nucleic acid, e.g., mRNA is present in peripheral blood monocytes (PBMCs) and / or detecting a cellular-mediated immune response to CMV peptides or proteins is present and / or HLA phenotyping and / or HLA genotyping. Embodiements can include a skin test.

Cancer immunology provides promising new avenues for cancer treatment but validation of potential neoantigens to target is costly and expensive. Analysis of MHC binding affinity, antigen processing, similarity to known antigens, predicted expression levels (as mRNA or proteins), self-similarity, and mutant allele frequency, provides screening method to identify and prioritize candidate neoantigens using sequencing data. Methods of the invention thereby save time and money by identifying the priority candidate neoantigens for further experimental validation.

The present invention relates to a method for treatment or prevention of an autoimmune disease in a patient, comprising: (a) Determining the HLA genotype of the patient; and (b) Subjecting the patient to a treatment regimen based on said genotype.

Disclosed is a rapid genetic method for detection of HLA genotype based on the loop-mediated isothermal amplification (LAMP) principles, and in particular, disclosed are a method and a kit for detection of HLA-B*1502 allele based on LAMP principles.

The invention provides a method for detecting HBB gene mutation and HLA genotyping based on the high throughput sequencing technology and a corresponding reagent kit. An adopted primer composition comprises a primer of closely-linked single nucleotide polymorphisms (SNP) within the 1 Mb range of the up stream and the down stream of the specific amplification human embryo beta-thalassemia HBB gene and primers of the closely-linked single nucleotide polymorphisms (SNP) within the ranges at the up stream of the LHA-A gene, between the HLA-A gene and the HLA-B gene, between the HLA-B gene and the HLA-DRA gene, between the HLA-DRA gene and the HLA-DQB1 gene and at the downstream of the HLA-DQB1 gene of the specific amplification human leucocyte antigen system. The method has the advantages of university, single nucleotide polymorphisms (SNP) sequencing, high throughput, low cost, high flexibility and strong specificity.

The invention provides a PCR-SBT method for HLA genotyping. Exons 1, 2, 3, 4, 5, 6, 7 of an HLA-A locus, an HLA-B locus and an HLA-C locus are subjected to genotyping. The method comprises the following steps of: (1) preparing human genomic DNA; (2) designing an amplification primer; (3) performing double digestion purification on an amplification product; (4) designing a sequencing primer and performing sequencing PCR on a purification product; (5) purifying a sequencing product by a sodium acetate-ethanol precipitation method and performing capillary electrophoresis sequencing; and (6) performing software analysis on the acquired sequence to determine genotypes thereof. The exons 1, 2, 3, 4, 5, 6, 7 of the HLA-A, B, C loci are subjected to full-length sequence sequencing, so that the full length of the related exons of the HLA-A, B, C loci and part of intron oligonucleotide sequences are obtained and the HLA genotyping is accurately performed.